Air Pollution and Health of COPD Patients

Effect of Air Pollution on Prognosis of Patients With Chronic Obstructive Pulmonary Disease and Its Underlying Biological Mechanism

This panel study aims to evaluate the effects of air pollutants on cardiopulmonary health of patients with chronic obstructive pulmonary disease (COPD) and explore the potential biological mechanisms.

Study Overview

• Status: Completed
• Conditions: Chronic Obstructive Pulmonary Disease
• Intervention / Treatment: Other: Air pollutants

Detailed Description

This panel study was conducted in a group of stable patients with COPD in Beijing, China. The health measurements including lung function, blood pressure and airway inflammation were conducted, and morning urine, exhaled breath condensate, saliva and venous blood were collected at the time of enrollment and at 3, 6 and 9 months after enrollment. Individual exposures to fine particulate matter (PM2.5), black carbon (BC), ozone (O3) and nitrogen dioxide (NO2) were performed for 24 hours at each follow-up. And the daily concentrations of air pollutants were collected from the Beijing Air Quality Real-time Publishing Platform and meteorological data were collected from the National Meteorological Information Center. The linear mixed effects model was used to analyze the association between air pollution and cardiopulmonary health in patients with COPD.

• Study Type: Observational
• Enrollment (Actual): 110

Contacts and Locations

Study Locations

• China
  • Beijing, China, 100191
    • Peking University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Stable COPD patients aged 40-80 in Beijing, China

Description

Inclusion Criteria:

• doctor-diagnosed stable COPD patients
• aged 40 to 80 years
• lived in Beijing for over one year before being recruited
• Agree to participate and sign the informed consent form.

Exclusion Criteria:

• Patients with a history of acute exacerbation in the last 1 month
• Patients with other respiratory diseases such as bronchiectasis and asthma.

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lung function	Lung function test was conducted.	Nine months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
COPD Assessment Test scores	COPD Assessment Test (CAT) scores were used to assess quality of life in COPD patients on a scale of 0 to 40, with higher scores associated with poorer outcomes.	Nine months
Modified British Medical Research Council (mMRC) Questionnaire score	Modified British Medical Research Council (mMRC) Questionnaire score was used to assess the severity of dyspnea on a scale of 0 to 4, with a higher score indicating a worse outcome.	Nine months
ST. George's Respiratory Questionnaire scores	ST. George's Respiratory Questionnaire (SGRQ) scores were used to assess quality of life in patients with COPD on a scale of 0 to 100, with higher scores indicating poorer outcomes.	Nine months
Blood pressure	Systolic and diastolic blood pressure of participants were measured at least three times by a trained technician.	Nine months
Respiratory inflammation	Fractional exhaled nitric oxide (FeNO) test was conducted.	Nine months
Airway and systemic oxidative stress levels	Exhaled Breath Condensate (EBC) and urine samples were collected for oxidative stress analysis.	Nine months
Systemic inflammation	Venous blood was collected for determination of systemic inflammatory biomarkers.	Nine months

Collaborators and Investigators

• Sponsor: Peking University
• Investigators: Principal Investigator: Furong Deng, Doctor, Peking University

Study record dates

Study Major Dates

• Study Start (Actual): October 12, 2021
• Primary Completion (Actual): June 30, 2024
• Study Completion (Actual): December 31, 2024

Study Registration Dates

• First Submitted: September 16, 2021
• First Submitted That Met QC Criteria: October 1, 2021
• First Posted (Actual): October 13, 2021

Study Record Updates

• Last Update Posted (Actual): June 3, 2025
• Last Update Submitted That Met QC Criteria: May 28, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Keywords: Air pollution; chronic obstructive pulmonary disease; cardiopulmonary health; biological mechanism
• Additional Relevant MeSH Terms: Pathologic Processes; Chronic Disease; Disease Attributes; Respiratory Tract Diseases; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: IRB00001052-21085

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No